992 related articles for article (PubMed ID: 19546609)
1. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
2. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
3. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
4. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
5. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
6. Predicting features of breast cancer with gene expression patterns.
Lu X; Lu X; Wang ZC; Iglehart JD; Zhang X; Richardson AL
Breast Cancer Res Treat; 2008 Mar; 108(2):191-201. PubMed ID: 18297396
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling: decoding breast cancer.
de Snoo F; Bender R; Glas A; Rutgers E
Surg Oncol; 2009 Dec; 18(4):366-78. PubMed ID: 19879448
[TBL] [Abstract][Full Text] [Related]
8. Current status of prognostic profiling in breast cancer.
Pusztai L
Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
[TBL] [Abstract][Full Text] [Related]
9. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
11. [Gene expression based multigene prognostic and predictive tests in breast cancer].
Pénzváltó Z; Mihály Z; Gyorffy B
Magy Onkol; 2009 Dec; 53(4):351-9. PubMed ID: 20071307
[TBL] [Abstract][Full Text] [Related]
12. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression.
Nagai MA; Fregnani JH; Netto MM; Brentani MM; Soares FA
Breast Cancer Res Treat; 2007 Nov; 106(1):49-56. PubMed ID: 17211533
[TBL] [Abstract][Full Text] [Related]
14. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
15. Challenges in projecting clustering results across gene expression-profiling datasets.
Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
[TBL] [Abstract][Full Text] [Related]
16. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
17. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Reid JF; Lusa L; De Cecco L; Coradini D; Veneroni S; Daidone MG; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2005 Jun; 97(12):927-30. PubMed ID: 15956654
[TBL] [Abstract][Full Text] [Related]
18. Clinical validation of a customized multiple signature microarray for breast cancer.
Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
[TBL] [Abstract][Full Text] [Related]
19. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
20. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.
Paik S
Oncologist; 2007 Jun; 12(6):631-5. PubMed ID: 17602054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
